Kallikrein 9 Antibody [Unconjugated]

Kallikrein 9 was detected in immersion fixed paraffin-embedded sections of human ovarian cancer tissue using 15 µg/mL Goat Anti-Human Kallikrein 9 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3486) overnight at 4 °C. Tissue was stained with the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Lower panel shows a lack of labeling if primary antibodies are omitted and tissue is stained only with secondary antibody followed by incubation with detection reagents. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

• Reactivity: Hu
• Applications: WB, IHC, IP
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

Kallikrein 9 Antibody [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human Kallikrein 9
  Asp20-Asn250
  Accession # Q9UKQ9
• Specificity: Detects human Kallikrein 9 in direct ELISAs and Western blots. In direct ELISAs and Western blots, less than 1% cross-reactivity with recombinant human KLK-1, -3, -4, -5, -6, -7, -8, -10, -11, -12, -13, -14, and -15 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: KLK9
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 5-15 ug/mL
  • Immunoprecipitation 25 ug/mL
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Kallikrein 9 Antibody [Unconjugated]

• EC 3.4.21
• EC 3.4.21.-
• EC 3.4.21.4
• Kallikrein 9
• Kallikrein-like protein 3
• kallikrein-related peptidase 9
• KLK9
• KLKL3
• KLK-L3
• KLK-L3kallikrein-9
• MGC50513

Background

The human tissue kallikrein (KLK) gene family contains 15 members that play important roles in cancer. Notably, kallikrein-1, also known as tissue kallikrein, cleaves kininogen to release the vasoactive kinin peptide, bradykinin or lysyl-bradykinin. Kallikrein-3, called prostate specific antigen (PSA), is an established tumor marker that aids in the diagnosis, staging, and follow up of prostate cancer. Kallikrein-4 is specifically expressed in the prostate and over-expressed in prostate cancer. Kallikrein-5 is widely expressed but found at high levels in skin, breast, brain and testis; over-expression is an indicator of poor prognosis in ovarian cancer. Kallikrein-8 is expressed in the brain and is a novel marker of ovarian and cervical cancer.

Human plasma kallikrein, a serine protease, is synthesized in the liver and circulates in the plasma bound to high molecular weight (HMW) kininogen or as a free zymogen. Once activated by its physiological activator, coagulation factor XII, it displays endopeptidase activity towards peptide bonds after arginine (preferred) and lysine. It cleaves HMW kininogen, its major physiological substrate, to release the potent vasodilator peptide bradykinin. It is also able to cleave a number of inactive precursor proteins to generate active products, such as plasminogen and prourokinase.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Kallikrein 9 Antibody (AF3486)(3)

Publications using AF3486

• NJ Hogrebe, P Augsornwor, KG Maxwell, L Velazco-Cr, JR Millman Targeting the cytoskeleton to direct pancreatic differentiation of human pluripotent stem cells Nat. Biotechnol., 2020-02-24;0(0):. 2020-02-24 [PMID: 32094658] (ICC, Human)
• Y Wang, L Lifshitz, K Gellatly, CL Vinton, K Busman-Sah, S McCauley, P Vangala, K Kim, A Derr, S Jaiswal, A Kucukural, P McDonel, PW Hunt, T Greenough, J Houghton, M Somsouk, JD Estes, JM Brenchley, M Garber, SG Deeks, J Luban HIV-1-induced cytokines deplete homeostatic innate lymphoid cells and expand TCF7-dependent memory NK cells Nat. Immunol., 2020-02-17;21(3):274-286. 2020-02-17 [PMID: 32066947] (ICC, Human)
• Chee J, Singh J, Naran A, Misso NL, Thompson PJ, Bhoola KD Novel expression of kallikreins, kallikrein-related peptidases and kinin receptors in human pleural mesothelioma. Biol. Chem., 2007-11-01;388(11):1235-42. 2007-11-01 [PMID: 17976017] (IHC-P, Human)

Bioinformatics

• Gene Symbol: KLK9
• Uniprot:
  • Q9UKQ9()